Drugs / Anti-CD19-CD3E-CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06373081 | Apr 2024 → Apr 2025 | Sjogren syndrome, anti-neutrophil antibody associated vasculitis, antiphospholipid syndrome, idiopathic inflammatory myopathy +2 | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD19-CD3E-CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06373081 ↗ |
| Modality | Cell therapy | “CAR-transduced autologous T cells administered intravenously” NCT06373081 ↗ |
| Route | Intravenous | “administered intravenously” NCT06373081 ↗ |
| Target | CD19 | “Autologous T-cells expressing a chimeric antigen receptor directed to CD19.” NCT06373081 ↗ |